Prelude Therapeutics/$PRLD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Prelude Therapeutics
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
- Ticker
- $PRLD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 79
- Headquarters
- Wilmington, United States
- Website
- preludetx.com
PRLD Metrics
BasicAdvanced
$378M
-
-$0.72
0.96
-
Price and volume
Market cap
$378M
Beta
0.96
52-week high
$6.83
52-week low
$1.15
Average daily volume
516K
Financial strength
Current ratio
4.072
Quick ratio
3.989
Long term debt to equity
0.111
Total debt to equity
0.132
Profitability
EBITDA (TTM)
-64.51
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-269.75%
Operating margin (TTM)
-294.76%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-27.15%
Return on equity (TTM)
-57.73%
Valuation
Price to revenue (TTM)
13.782
Price to book
2.83
Price to tangible book (TTM)
2.83
Price to free cash flow (TTM)
-9.293
Free cash flow yield (TTM)
-10.76%
Free cash flow per share (TTM)
-0.395
Growth
Revenue change (TTM)
220.34%
Earnings per share change (TTM)
-56.13%
3-year earnings per share growth (CAGR)
-32.59%
What the Analysts think about PRLD
Analyst ratings (Buy, Hold, Sell) for Prelude Therapeutics stock.
Analyst projections of the future price of Prelude Therapeutics stock.
Bulls say / Bears say
The FDA cleared PRT13722’s IND in September, with Phase 1 enrolment expected in the fourth quarter of 2026. Earlier preclinical work showed durable complete tumour regressions in several HR+/HER2- breast-cancer models, giving Prelude a clear near-term clinical catalyst. (GlobeNewswire, GlobeNewswire)
PRT12396 has entered a first-in-human Phase 1 study in polycythaemia vera and myelofibrosis, targeting the JAK2V617F mutation that is common in these diseases. The programme also has an exclusive option agreement with Incyte, creating a potential route to outside development support. (GlobeNewswire)
Prelude’s degrader-antibody-conjugate platform adds optionality beyond its two clinical programmes. Its SMARCA2/4 and CDK9 payloads have shown better efficacy and tolerability than traditional cytotoxic ADCs in head-to-head xenograft testing, and the company already has a partnership with AbCellera while seeking more licences. (GlobeNewswire)
Both lead programmes remain early and unproven in people: PRT12396 is only in Phase 1, while PRT13722 is due to start Phase 1 enrolment in the fourth quarter. There is therefore no disclosed human proof yet that either candidate is safe or effective. (GlobeNewswire, GlobeNewswire)
The April fundraise brought in approximately $90 million through 18.0 million new shares and pre-funded warrants for up to 2.25 million more shares. This extends the runway but dilutes existing shareholders and signals that further capital may eventually be needed before any product revenue. (GlobeNewswire)
Prelude is not alone in pursuing KAT6 biology. Olema’s competing KAT6 inhibitor was already in Phase 1 and had preliminary clinical data due for presentation, whereas Prelude’s claimed advantages for selective degradation still rest on preclinical evidence. (GlobeNewswire, GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 21 Sept 2026.
PRLD Financial Performance
Revenues and expenses
PRLD Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing PRLD
AllEURGBP
Fund name | Fund size | $PRLD weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.